Navigation Links
Unigene's Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist
Date:11/30/2011

ise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward- looking statements, including with respect to clinical studies of one of our licensees. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These known and unknown risk factors include, but are not limited to: the delay in obtaining or the failure to obtain regulatory approvals for our products and the products of our licensees that may generate royalty and milestone payments to us, our ability to achieve product sales and royalties, competition, our dependence on other companies to commercialize, manufacture and sell products using our technologies, the ability of our products to gain market acceptance and increase market share, the uncertainty of results of animal and human testing, the risk of product liability and liability for human clinical trials, our dependence on patents and other proprietary rights and the risks associated with patent litigation, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, general economic and business conditions, our history of losses and ability to achieve profitability, litigation and other risk factors discussed in our Securit
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
2. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
3. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
4. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
5. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
6. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
7. Nventa Develops Proprietary Vaccine Adjuvant
8. First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval
9. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
10. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
11. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... (Nasdaq: LMNX ) today announced that it expects ... Monday, February 3, 2014. A press release announcing the results ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management will ... financial results for the fourth quarter and twelve months ended ...
(Date:1/14/2014)... , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC ... guide with accompanying instrumentation to place and insert the ... the soft tissue (e.g. ligament) repair or reconstruction as ... heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a ... therapeutics for Alzheimer,s disease (AD) and related neurodegenerative disorders, ... Valhalla, NY as of January ... space at New York Medical College. Oligomerix, ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... 21, 2011 MicroAire Surgical Instruments ... for carpal tunnel syndrome.  MicroAire,s new device, called ... assembly that allows surgeons to treat carpal tunnel ... wrist – thereby avoiding full open-hand surgery through ...
... 2011 Seal Shield LLC today announced ... for the iPad.  The product has been designed specifically ... use in hospital settings. The Seal Shield ... which is resistant to liquids including blood and bleach. ...
Cached Medicine Technology:MicroAire Introduces New SlimLine™ ECTR Cannula 2
(Date:4/22/2014)... 2014) The International Communication Association will hold ... Washington. The theme of the 2014 conference will ... networked and digital society. , Featuring over 2,300 ... 2,200 Communication scholars representing over 40 countries, the ... conference in the world. This year,s conference features ...
(Date:4/22/2014)... 22, 2014Hemoglobin A1c is the standard measurement for assessing ... levels of A1c are typically measured every few months ... data-based model that accurately estimates A1c using self-monitored blood ... & Therapeutics ( DTT ), a peer-reviewed journal ... available free on the DTT website at ...
(Date:4/22/2014)... April 2014. The latest scientific advances and emerging therapies ... 2014, the main annual meeting of the Heart Failure ... Journalists will also hear breaking news on acute heart ... Failure, which is part of the main congress. , ... Greece, at the Megaron Athens International Conference Centre (MAICC). ...
(Date:4/22/2014)... at the University of Utah (U of U) has ... separate cases, U of U researchers and their colleagues ... Journal of Human Genetics . The software, Phevor (Phenotype ... unknown gene mutations by analyzing the exomes, or areas ... made, in individual patients and small families. , ...
(Date:4/22/2014)... Nearly 7 in 10 Americans support mandated coverage of ... by researchers at the University of Michigan Health System. ... age of 18 at home, and adults with private ... adults to support universal coverage of birth control medications, ... Journal of the American Medical Association ( JAMA ...
Breaking Medicine News(10 mins):Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2Health News:The world's largest heart failure congress 2Health News:The world's largest heart failure congress 3Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 2Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 3Health News:More than two-thirds of Americans support mandated coverage of birth control in health plans 2
... BOULDER, Colo., Aug. 25 Bioelements has ... www.ro o m214.com ) to support research, ... and online initiatives. "Room 214 was chosen as our ... consumer behavior," said Callie Lushina, Vice President of Marketing for ...
... , , Says Damage ... , , WASHINGTON, Aug. 25 The ... ) board to remove CEO John Mackey as Chairman and to begin ... Foods, lead independent director, Dr. John Elstrott, yesterday afternoon. Citing the ...
... ... across the nation take a collective step to improve their health through exercise and increased ... that may unlock the secret to living longer and healthier lives. , ... Cambridge, MA (Vocus) August 25, 2009 -- This ...
... CINCINNATI, Aug. 25 HealthWarehouse.com, Inc. (OTC Bulletin Board: ... financial results for the second quarter ended June 30, 2009. ... heavy growth in prescription sales and pharmacy transfers. Gross margins ... quarter was $396,271. , , "Consumers are ...
... , LOUISVILLE, Colo., Aug. 25 According ... Reconstructive Surgery Journal , the official journal of the American ... to be a safe and effective treatment option for fat ... Lipo to be an enhanced fat removal and transfer system ...
... in unpasteurised food has been detected in unusually high ... with the condition pre-eclampsia. These results are important ... indicator of pre-eclampsia and may help scientists to understand ... Scientists at the University of Leeds took blood ...
Cached Medicine News:Health News:Bioelements Selects Room 214 as Their Social Media and Online Marketing Agency 2Health News:CtW Investment Group Calls for Whole Foods Board to Remove Chair and CEO John Mackey 2Health News:CtW Investment Group Calls for Whole Foods Board to Remove Chair and CEO John Mackey 3Health News:CtW Investment Group Calls for Whole Foods Board to Remove Chair and CEO John Mackey 4Health News:Aging Science Leaders to Gather During Active Aging Week to Encourage Discovery in Healthy Living and Longevity 2Health News:Aging Science Leaders to Gather During Active Aging Week to Encourage Discovery in Healthy Living and Longevity 3Health News:HealthWarehouse.com, Inc. Announces Second Quarter Financial Results; Revenues Increase Significantly Over Second Quarter 2008 2Health News:HealthWarehouse.com, Inc. Announces Second Quarter Financial Results; Revenues Increase Significantly Over Second Quarter 2008 3Health News:New Study Reveals VASER(R) Lipo to be the New Standard of Care for Body Contouring and Fat Transfer Procedures 2Health News:New Study Reveals VASER(R) Lipo to be the New Standard of Care for Body Contouring and Fat Transfer Procedures 3Health News:New link between pre-eclampsia and diet 2
... time-consuming tasks and delivers consistently ... productivity and ensure testing accuracy ... offers automated reticulocyte counts and ... excellent sensitivity, specificity and efficiency ...
The Fathom Guidewire combines a nitinol hypotube distal segment with advanced microfabrication technology, creating a design that revolutionizes access of the most tortuous vasculature....
... bi-polar CryoCor CryoBlator Series of Cryoablation Catheters ... catheter design with the two-stage cooling system ... maximize the delivery of cryoenergy to the ... work together to create the transmural lesions ...
... 5 software, the latest from Quality ... management application designed specifically for implementing ... system. The superior design, functionality, security, ... tool for managing a quality program., ...
Medicine Products: